▲ Peaking
Business
Novo’s blockbuster hopes for CKD program dwindle after more phase 3 trials scrapped
Novo Nordisk faces a setback in its chronic kidney disease program after terminating two Phase III trials for ziltivekimab.
2 trends tracked about this subject — the full history, oldest to newest below.
Novo Nordisk faces a setback in its chronic kidney disease program after terminating two Phase III trials for ziltivekimab.
Analysts are closely monitoring the impact of intismeran following a landmark Phase III clinical trial victory in the cancer vaccine sector.